Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
93 hedge funds and large institutions have $389M invested in Global Blood Therapeutics, Inc. in 2016 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 48 increasing their positions, 11 reducing their positions, and 10 closing their positions.
336% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 11
180% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 10
69% more capital invested
Capital invested by funds: $229M → $389M (+$159M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
42% more call options, than puts
Call options by funds: $2.21M | Put options by funds: $1.55M
24% more funds holding
Funds holding: 75 → 93 (+18)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$24.2M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$19.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.4M |
| 4 |
PA
Perceptive Advisors
New York
|
+$18.4M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$9.52M |
| 2 |
RI
RTW Investments
New York
|
-$1.89M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.78M |
| 4 |
Goldman Sachs
New York
|
-$1.22M |
| 5 |
DA
DSC Advisors
Chicago,
Illinois
|
-$1.03M |
GBT Hedge Fund Activity: Q2 2016 in Review
93 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q2 2016, worth a combined $389M — up 69% from $229M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new GBT positions and 10 closed out — a net gain of 18 holders — while 48 added to existing stakes and 11 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $24.2M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $9.52M sold.
- 93 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q2 2016, up from 75 in Q1 2016.
- Funds reported $389M of Global Blood Therapeutics, Inc. stock for Q2 2016, up 69% quarter-over-quarter.
- 28 funds opened new Global Blood Therapeutics, Inc. positions in Q2 2016 and 10 closed out, a net change of +18 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q2 2016 was Wellington Management Group, an estimated $24.2M added.
- The largest Global Blood Therapeutics, Inc. seller in Q2 2016 was Baker Bros. Advisors, an estimated $9.52M sold.
Based on aggregated 13F filings for Q2 2016.